BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Johnson & Johnson (JNJ) CEO Dodges Bullet in Risperdal Drug Case


9/21/2012 7:54:27 AM

A Philadelphia judge said Thursday that Johnson & Johnson chief executive officer Alex Gorsky cannot be called as a trial witness by lawyers for a 17-year-old boy whose family sued the company because he grew breasts after taking Risperdal, an antipsychotic drug made by J&J. In a big victory for the health-care giant, Philadelphia Common Pleas Court Judge Arnold New agreed to the request by J&J defense lawyers to quash the subpoena from the boy's attorneys. J&J said in a motion that Gorsky was scheduled to be in Asia on business. But the company clearly wanted to avoid having its CEO called to the stand to answer - publicly, under oath - allegations of inappropriate marketing of the drug to children and harmful side effects.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->